Extending Heart Viability to 12+ Hours for Global Transplantation
Limenbio presents its patented HIPPER (High-Pressure Gas Perfusion) system — a high-pressure gas perfusion technology.
Our goal is to overcome the critical 4-hour barrier that limits the life of a donor heart and extend its viability window to 12 hours or more.
This allows organs to be transported over long distances, saving hundreds of lives that are currently lost due to logistical constraints.
Our goal is to overcome the critical 4-hour barrier that limits the life of a donor heart and extend its viability window to 12 hours or more.
This allows organs to be transported over long distances, saving hundreds of lives that are currently lost due to logistical constraints.
COMPETITIVE ADVANTAGES
3x longer organ storage
and better viability compared to the current standard of static cold storage
Autonomous
does not require constant power supply and active cooling
10x lower
production and operating costs vs. standard of care
1.0
Ease of use ensure high reliability and fault tolerance
CHARACTERISTICS
High-Pressure Perfusion
(HIPPER) system
(HIPPER) system
3.0
Intelligent control module
2.0
Proprietary Lifecycle Management Architecture
CHARACTERISTICS
High-Pressure Perfusion
(HIPPER) system
(HIPPER) system
1.0
Ease of use ensure high reliability
and fault tolerance
and fault tolerance
3.0
Intelligent control module
2.0
Proprietary Lifecycle Management Architecture
COMPARISON
Active gaseous perfusion extends the preservation window to over 12 hours, transforming transplantation into a scheduled surgery and expanding the donor catchment area
> 12 hours
HIPPER Limenbio system
Cold Static Storage
An integrated peristaltic pump delivers pulsatile gaseous perfusion, ensuring deep tissue oxygenation and metabolic support without the edema risks associated with liquid perfusion
Active Gas Perfusion
This passive system lacks oxygen delivery, leading to progressive hypoxia, metabolite accumulation, and organ degradation
Passive Hypothermia
Precise regulation of pressure, temperature, and gas composition ensures optimal organ viability
Tailored Environment
Passive cold packs can reach dangerous sub-zero temperatures (e.g., -20°C), posing a risk of contact-mediated freezing injuries
Uncontrolled Cooling
The autonomous system reduces operational costs 10-fold compared to normothermic perfusion by eliminating expensive consumables and the need for specialized personnel
Mid CapEx / Low OpEx
Low initial cost but high "cost of failure" (discarded organs)
Low CapEx / High Wastage
Passive hypothermia restricts heart viability to approximately 4 hours, creating logistical urgency and increasing the risk of primary graft dysfunction
< 4 hours
Gas Leak Protection
The system is able to maintain stable pressure without leaks for up to 90 days
Safe organ placement
A tailored 3D-printed suspension allows the organ to float in a gas environment, preventing bedsores caused by contact with solid surfaces
Real-time monitoring
Internal sensors monitor temperature and pressure within the chamber and organ vessels in real time, creating a verifiable log of storage conditions
Proprietary software controls the
preservation cycle from start to finish: induction (preparation), stasis (stability), and resuscitation (release). The system provides fully automated parameter control and continuous real-time monitoring to ensure graft integrity at every stage
preservation cycle from start to finish: induction (preparation), stasis (stability), and resuscitation (release). The system provides fully automated parameter control and continuous real-time monitoring to ensure graft integrity at every stage
SOFTWARE
TECHNOLOGY VALIDATION
PATENTS
The technology is protected by
the international application WO2025165261 (“Method for preserving a donor organ and container for its preservation”)
the international application WO2025165261 (“Method for preserving a donor organ and container for its preservation”)
GRANT SUPPORT
The technology is protected by
the international application WO2025165261 (“Method for preserving a donor organ and container for its preservation”)
the international application WO2025165261 (“Method for preserving a donor organ and container for its preservation”)
PARTNERSHIPS
Validation was carried out at leading centers, including the E.N. Meshalkin National Medical Research Center and the Institute of Immunology and Physiology (Ural Branch of the Russian Academy of Sciences)
Alexander Chernyavsky
MD, PhD Professor, Corresponding Member of the Russian Academy of Sciences Director General, E.N. Meshalkin National Medical Research Center
«Data obtained during our joint pilot study demonstrate the significant potential of this methodology as a viable solution for extended-duration organ preservation. The scientific novelty of this project lies in providing critical new insights into how hyperbaric oxygenation preserves the morphofunctional integrity of donor hearts»
We are looking for
Partnership in transplantological area to run further experiments/preclinical trials
